Domain Invest

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Friday, 19 October 2007

Exubera: Fun with the Classics

Posted on 08:15 by Unknown
(With apologies to Joseph Heller.)

… We will courtmartial you if you turn our deal down, even though it would raise a lot of questions and be a terrible black eye for Colonel Cathcart Kindler.

Colonel Cathcart Kindler winced at the words “black eye” and, without any apparent premeditation, hurled his slender onyx-and-ivory cigarette holder Exubera inhaler down viciously on the wooden surface of his desk. “Jesus Christ Hank McKinnel!” he shouted unexpectedly. “I hate this goddam cigarette holder Exubera inhaler!” The cigarette holder Exubera inhaler bounced off the desk to the wall, ricocheted across the window sill to the floor and came to a stop almost where he was standing. Colonel Cathcart Kindler stared down at it with an irascible scowl. “I wonder if it’s really doing me any good.”

“It’s a feather in your cap with General Peckem Pfizer’s ego, but a black eye for you with General Scheisskopf the investors,” Colonel Korn informed him with a mischievous look of innocence.

“Well, which one am I supposed to please?”

“Both.”

“How can I please them both? They hate each other. How am I ever going to get a feather in my cap from General Scheisskopf the investors without getting a black eye from General Peckem Pfizer’s ego?”

“March Biogen.”

“Yeah, March Biogen. That’s the only way to please him Pfizer’s ego. March Biogen. March Biogen.”
Email ThisBlogThis!Share to XShare to Facebook
Posted in Exubera, Pfizer | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • While You Were Settling
    Well, it was an interesting weekend: the writers' strike may have been settled, Obama swept (and won a Grammy), and there was an unusual...
  • EPO Relabeling: Its Not the Black Box, Its What FDA Says About the Black Box
    Whoever said actions speak louder than words hasn’t been paying attention to the regulatory response to drug safety issues involving the ane...
  • The Wacky World of Generics: Fosamax Edition
    Today, Merck bids a fond farewell to its Fosamax franchise, as the first generic versions enter the market. Three generic firms are enteri...
  • Higher Tax, Fewer Deals?
    The IN VIVO Blog has been somewhat mum on the carried interest debate. Frankly, this topic is being covered to death elsewhere (The link g...
  • CardioNet's Not So Big Surprise
    Riddle us this. When is news not news at all? When it’s involving CardioNet Inc.’s Friday filing for an IPO . See, this filing was essential...
  • While You Were Staying Put
    It's always sunny in ... London? Lets kick off the weekend wrap-up by highlighting a trio of stories from The Times about incoming Glax...
  • While You Were Almost Upsetting
    We've been told by certain football (soccer) fans that there are not enough allusions to the beautiful game in our weekend roundups. So ...
  • FDA’s Search for a Drug Chief Not Going Well: An Internal Candidate Emerges
    We know all of you have been passing the time following the Presidential Primaries when the race you’re really interested in is who the next...
  • While You Were Redesigning Your Blog
    Does our blog look big in this? You may have noticed a few changes round these parts, and we hope you like them. No, not that the pace of o...
  • The Downsizing Opportunity: Pipeline on the Cheap?
    The IN VIVO Blog was in Michigan last week, attending a profiting-from-downsizing symposium. Would Pfizer—we wondered at the Michigan Growth...

Categories

  • Abbott
  • activist shareholders
  • ADHD
  • advisory committees
  • alliances
  • Alnylam
  • Alzheimer's disease
  • Amgen
  • Andrew von Eschenbach
  • Andrew Witty
  • Astellas
  • AstraZeneca
  • Avandia
  • Avastin
  • Barack Obama
  • Barr
  • Bayer
  • Big Pharma
  • BIO
  • Biogen Idec
  • biologics
  • biosimilars
  • blogging
  • BMS
  • Boston Scientific
  • brand names
  • business development
  • business models
  • cancer vaccines
  • Carl Icahn
  • CBO
  • CDER
  • Celgene
  • Cephalon
  • China
  • clinical development
  • CMS
  • co-promotes
  • comparative effectiveness
  • conference
  • Congress
  • consumer genomics
  • corporate culture
  • corporate governance
  • corporate venture capital
  • CVS Caremark
  • Cytyc
  • David Kessler
  • deals of the week
  • debt financing
  • Diabetes
  • diagnostics
  • Dick Clark
  • drug approvals
  • drug delivery
  • drug discovery
  • drug eluting stents
  • Drug Pricing
  • drug safety
  • drug samples
  • DTC Advertising
  • e-health
  • Eisai
  • Elan
  • Eli Lilly
  • Emphasys
  • emphysema
  • Endo
  • epo
  • Euro-Biotech Forum
  • Exits
  • Exubera
  • FDA
  • FDA/CMS Summit
  • FDAAA
  • Film and TV
  • financing
  • FOBs
  • Forest Labs
  • Galvus
  • gene therapy
  • Genentech
  • General Electric
  • generics
  • Genzyme
  • Gleevec
  • Google
  • GSK
  • Guidant
  • haircuts
  • Happy Holidays
  • HCV
  • Headhunting
  • Health Care Reform
  • hedge funds
  • Henry Waxman
  • hGH
  • HHS
  • Hillary Clinton
  • Hologic
  • hostile takeovers
  • hypertension
  • ImClone
  • IMS Health
  • In vitro diagnostics
  • In3
  • India
  • insomnia
  • instrumentation
  • insulin
  • Inverness
  • IP
  • IPO
  • IPO pricing
  • Isis Pharmaceuticals
  • Israel
  • IT
  • JAMA
  • Januvia
  • Japan
  • John McCain
  • Johnson and Johnson
  • JP Morgan
  • LaMattina
  • lawsuits
  • layoffs
  • legislation
  • Life-Cycle Management
  • Lipitor
  • Lucentis
  • management succession
  • Mark McClellan
  • marketing
  • Martin Mackay
  • medical devices
  • Medicare
  • Medicare Part D
  • Medimmune
  • Medtech Insight
  • Medtronic
  • Merck
  • Merck-Serono
  • mergers and acquisitions
  • Michael McCaughan
  • Millennium
  • mmm beer
  • MRI
  • multiple sclerosis
  • music
  • nanotechnology
  • NEJM
  • new drug approvals
  • new funds
  • NICE
  • NicOx
  • NIH
  • Nobel Prize
  • Novartis
  • Novo Nordisk
  • Nycomed
  • off-label promotion
  • oncology
  • ophthalmology
  • Orthopedics
  • osteoporosis
  • OTC drugs
  • Out-Partnering
  • Oxycontin
  • pain
  • Part D
  • Patient Advocacy
  • PDUFA
  • personalized medicine
  • Pfizer
  • pharmacy benefits
  • PhRMA
  • politics
  • poll results
  • PR
  • prasugrel
  • Presidential Election
  • Press Release of the Week
  • Primary Care
  • private equity
  • Procter and Gamble
  • PSA
  • Purdue Pharma
  • rare diseases
  • reimbursement
  • research and development productivity
  • research and development strategies
  • reverse mergers
  • rimonabant
  • RiskMAP
  • RNAi
  • Roche
  • Roger Longman
  • royalties
  • sales forces
  • Sanofi-aventis
  • Schering-Plough
  • Science Matters
  • Sepracor
  • shameless self-promotion
  • share buybacks
  • Shire
  • Sirtris
  • Smith and Nephew
  • Solvay
  • SPACs
  • spec pharma
  • spin-outs
  • sports
  • Start-Up
  • statins
  • Steve Nissen
  • Stryker
  • Supreme Court
  • Takeda
  • Teva
  • Thanksgiving
  • The RPM Report
  • UCB
  • vaccines
  • Velcade
  • Ventana
  • venture capital
  • venture debt
  • Venture Round
  • Vertex
  • Vioxx
  • Vytorin
  • Wacky World of Generics
  • While You Were ...
  • Wyeth
  • Zetia
  • Zimmer
  • ZymoGenetics

Blog Archive

  • ►  2008 (76)
    • ►  February (25)
    • ►  January (51)
  • ▼  2007 (329)
    • ►  December (32)
    • ►  November (42)
    • ▼  October (37)
      • Dicerna Crashes RNAi Party
      • Nail in the Coffin for GPC?
      • How Do Some of the Biggest Deals the Year Measure ...
      • Take the Money…or Let it Roll?
      • While You Were Sweeping
      • Deals of the Week! Inaugural Edition
      • The Chinese Gene Therapy Hotspot
      • Amgen Feels the Effects of CMS’ Long Shadow
      • Who Do You Buy?
      • Cracks in Crucible of Evidence-Based Medicine Crea...
      • Schering-Plough's Wake Up Call
      • While You Were Coming Back
      • Exubera: Fun with the Classics
      • Exdoomera: Why Is Sanofi-Aventis Smiling?
      • Biosimilars in Europe: Docs Decide
      • Musical Chairs at Novartis, Except When the Music ...
      • The Biogen Idec Sale: It’s About Revenues – Not Bi...
      • FDA Sides With CMS in EPO Battle; Labeling Change ...
      • Headline Risk: Drug Prices on Capitol Hill
      • Genentech Gets Tough: Who is the Target?
      • While You Were Considering the Alternatives
      • Another Reason to Watch C-SPAN
      • For IPO and M&A Exits, One Hand Washes the Other
      • $80 million upfront? About Average
      • Forsight Scores Big
      • Spec Pharma: Wrong Bandwagon, Guys
      • Shire’s Clean-Out: Dynepo Next?
      • Chomp! Wyeth Snaps Up Haptogen
      • While You Were Watching the Upsets
      • Venture Round: Ascension Raises Second Fund
      • If Hamlet Were a VC
      • How Much Does Pfizer Want to Succeed?
      • On the Beach at St. Tropez
      • Dollens: Reimbursement Uncertainty May Slow Innova...
      • High Noon at Myogen
      • Don't Miss Dollens
      • While You Were Winning the NL East!
    • ►  September (33)
    • ►  August (29)
    • ►  July (39)
    • ►  June (39)
    • ►  May (43)
    • ►  April (16)
    • ►  March (13)
    • ►  February (5)
    • ►  January (1)
  • ►  2006 (8)
    • ►  December (3)
    • ►  November (5)
Powered by Blogger.

About Me

Unknown
View my complete profile